What is Osteoarthritis?
Osteoarthritis is the most common form of arthritis and generally affects the bones that bear the body’s weight. While this medical condition cannot be reversed, medications and injections have been found to be effective in the reducing the pain caused due to osteoarthritis. Drugs such as NSAIDs, analgesics, corticosteroids, and viscosupplement agents are being used widely to manage osteoarthritis.
The osteoarthritis therapeutics market is a highly fragmented market and has presence of various players. The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).
Download PDF Brochure@
Expected Revenue Growth:
The osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025.
Major Growth Boosters
The growth of this market is driven by significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number of sports injuries.
Sanofi held the leading position in the global viscosupplementation agents market in 2019. The company offers Synvisc and Synvisc One for the treatment of pain associated with osteoarthritis. These drugs are marketed in more than 60 countries. The company invests significantly in R&D activities. In 2019, it invested USD 6.74 billion in R&D, which consisted of 16.7% of the company revenue. Sanofi showcases its products and participates in global events to increase its market visibility. The company has established a significant footprint in North America, Europe, Africa, and the Middle East. Its global footprint helps it in generating revenue from different regions.
Zimmer Biomet Holdings, Inc. (US)
Zimmer Biomet held second place in the global viscosupplementation agents market in 2019. The company offers viscosupplement-based injections for the treatment of osteoarthritis. Zimmer Biomet Holdings operates in more than 25 countries and markets its products in more than 100 countries across the Americas, Europe, and the Asia Pacific. Some of its key subsidiaries include Zimmer Spine, Inc. (US), Biomet, Inc. (US), Zimmer GmbH (Switzerland), and Zimmer Germany GmbH.
Request Sample Pages@
Geographical Growth Scenario:
“Europe commanded the largest share of the osteoarthritis therapeutics market in 2020.”
On the basis of region, the osteoarthritis therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, Europe commanded the largest share of the osteoarthritis therapeutics market. The large share of this market segment can be attributed to the rising incidence of osteoarthritis, rising geriatric population, and increasing obesity rates in several European countries, coupled with the rising number of injuries due to sports and road accidents.
Key developments in the Industry:
# In 2020, GlaxoSmithKline Plc (UK) launched Voltaren in the US.
# In 2020, Horizon Therapeutics Plc (Ireland) expanded its presence in the US.
# In 2019, Kitov Pharma Ltd. (Israel) entered into an agreement with Coeptis Pharmaceuticals which has helped in the efficient distribution and commercialization of Consensi.
# In 2018, Atnahs established a sales office in Dubai, UAE.
# In 2017, Flexion Therapeutics, Inc. (US) received FDA Approval for ZILRETTA